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Abstract
Background: U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART)
as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and
ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes.
Methods: We analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a
first reported CD4+ ,350 cells/uL or AIDS-defining illness) from 14 U.S. cohorts of the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD). Using propensity score matching and Cox regression, we assessed
ART initiation (within 6 months following eligibility) and virologic suppression (within 1 year) based on differences in two
state ADAP features: the amount of state funding in annual ADAP budgets and the implementation of waiting lists. We
performed an a priori subgroup analysis in persons with a history of injection drug use (IDU).
Results: Among 8,874 persons, 56% initiated ART within six months following eligibility. Persons living in states with no
additional state contribution to the ADAP budget initiated ART on a less timely basis (hazard ratio [HR] 0.73, 95% CI 0.60–
0.88). Living in a state with an ADAP waiting list was not associated with less timely initiation (HR 1.12, 95% CI 0.87–1.45).
Neither additional state contributions nor waiting lists were significantly associated with virologic suppression. Persons with
an IDU history initiated ART on a less timely basis (HR 0.67, 95% CI 0.47–0.95).
Conclusions: We found that living in states that did not contribute additionally to the ADAP budget was associated with
delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued
assessment of the role of ADAPs and their features that facilitate prompt treatment is needed.
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Introduction
Reducing HIV-related health disparities is a priority of the
United States (U.S.) National HIV/AIDS Strategy (NHAS) [1].
Many U.S. studies have demonstrated marked disparities in HIV
health care use and outcomes by factors such as race/ethnicity [2],
insurance status [3], and transmission risk [4,5]. For example,
people with HIV infection who use illicit drugs have been found to
be less likely to receive antiretroviral therapy (ART) [6,7],
although gaps have been decreasing in more recent years [8]/
Furthermore, geographic variation has been linked with differ-
ences in treatment initiation [7,9], hospitalizations [10,11], and
mortality [12] in HIV-infected people. State policy differences
likely contribute to geographic disparities; individuals infected with
HIV are often dependent on public health care services [13],
whose guiding policies are largely determined at the state level.
In particular, differences by state response to the Ryan White
CARE Act Part B AIDS Drug Assistance Programs (ADAPs),
which are used by about one-quarter of HIV-infected individuals
in care in the United States [13], may affect the timeliness of
obtaining treatment, as well as the benefits of such treatment. State
ADAPs act as the ‘‘payer of last resort’’ in providing ART and
other prescription medications to eligible people with HIV
infection [14]. People are eligible for ADAP services if they do
not have their own prescription drug coverage and do not qualify
for coverage through Medicare or their own state’s Medicaid
program (i.e., the inadequately insured, the less sick, and/or the
working poor). While ADAPs receive federal funding annually
through the Ryan White HIV/AIDS Program, each state
administers its program independently. As a result, ADAPs differ
in many ways, including the additional criteria used to define who
is eligible for ADAP assistance, the comprehensiveness of the state
ADAP drug formulary, and the procurement of additional funding
by the ADAP through sources such as state general revenue [14].
This last factor is relevant because federal allocations may not
cover the full needs of a state, and therefore many states
supplement the ADAP budget using monies from state funds,
which in Fiscal Year 2011 made up 16% of the national ADAP
budget [15]. Additionally, some state ADAPs over the years have
instituted enrollment waiting lists, an action that has been
particularly scrutinized, since these lists may delay people from
receiving ART, which in turn prevents them from benefiting
clinically from timely ART [16,17]. Waiting lists reached peak use
in 2011, when 14 states had an active waiting list, representing
9,298 people who had applied for ADAP services but were not yet
able to access medications through their states’ programs [18].
The published research on the clinical consequences of specific
features of ADAPs, primarily based on mathematical modeling,
has found the overall program to be cost-effective [19], and that
more generous state ADAPs are associated with better health
outcomes, including a lower incidence of opportunistic illnesses
and lower mortality [20–22]. Empirical data from observational
studies offer an opportunity to corroborate these findings and
better understand potential barriers to ADAP enrollment and
therefore timely initiation of treatment. Such information is
important as states manage their programs under increasingly
greater client demand and limited resources [18,23].
To understand the association between state ADAP policies and
treatment outcomes, we assessed differences in ART initiation and
viral load suppression among newly treatment-eligible participants
in U.S. cohorts of the North American AIDS Cohort Collabora-
tion on Research and Design (NA-ACCORD), a collaboration of
prospective cohort studies of HIV-infected individuals in the U.S.
and Canada, between 2001 and 2009. We compared these
outcomes based on two potentially unfavorable ADAP circum-
stances: not having additional state funding in the annual ADAP
budget and the use of waiting lists. Our research question was
whether individuals living in states under each of these circum-
stances were less likely to have timely ART initiation and virologic
suppression, compared with similar individuals not living in states
under the same circumstances. A secondary question was whether
these differences were more pronounced among those with a
history of injection drug use. We hypothesized that effects would
be greater in this population, owing to their greater needs with
respect to engagement in care and starting treatment [24,25].
Methods
Data source and study population
NA-ACCORD is a collaboration of single- and multi-site HIV
cohorts that includes over 100,000 individuals from more than 100
research sites in the U.S. and Canada [26]. At least annually, each
participating NA-ACCORD cohort submits standardized data
regarding enrolled participants’ demographic characteristics,
prescribed antiretroviral therapies, laboratory tests, clinical diag-
noses, and vital status to a centralized Data Management Core,
where the data undergo quality control for completeness and
accuracy before being combined into harmonized analysis files.
The source population for our analyses consisted of HIV-
infected individuals in the NA-ACCORD who were newly eligible
to initiate ART between 2001 and 2009, based on existing
treatment guidelines during this period (an incident AIDS-defining
event or CD4+ lymphocyte [CD4+] count recorded ,350 cells/
uL) [27] from 14 U.S. cohorts. Inclusion criteria included known
residence within a U.S. state, no prior CD4+ counts ,350 cells/
uL or AIDS-defining illnesses documented, at least two CD4+
counts in the study period, and no prior use of ART documented.
Because we were interested in answering the question of
whether individuals would have had different outcomes if they did
not live in a state without a particular ADAP characteristic, we
limited certain analyses to a subset of individuals who lived in
states with that particular feature in place at the time of ART
eligibility, and similar individuals who lived in states without that
feature.
In a secondary analysis, we examined individuals with a
documented history of injection drug use (IDU). To account for
potential underreporting of IDU, we also included individuals
without a documented history of IDU but with a diagnosis of
hepatitis C infection recorded in the absence of either a report of
hemophilia, contact with blood products, or among men, sex with
men. While this may have included some individuals without a
history of IDU, we conducted sensitivity analyses excluding these
additional individuals.
Ethics: The activities of the NA-ACCORD have been reviewed
and approved by the local institutional review boards (IRBs) for
each site. This study was determined to not qualify as human
subjects research by the Johns Hopkins Bloomberg School of
Public Health IRB.
Outcomes of interest
Our first outcome of interest was time to ART initiation, using
the date of ART eligibility (i.e., the first date that an incident
AIDS-defining illness or a CD4+ count ,350 cells/uL was
recorded) as the time origin. Time to ART initiation was defined
as the duration between the date of eligibility and the date an ART
regimen was prescribed (denoted in the medical record), or if this
was not available, when a regimen was started (denoted by self-
report). Time was censored at six months after eligibility to focus
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on more timely treatment initiation. ART regimens comprised at
least three active antiretroviral agents, including a protease
inhibitor, a non-nucleoside reverse transcriptase inhibitor, an
entry inhibitor, or an integrase strand transfer inhibitor; or three
nucleoside reverse transcriptase inhibitors, including abacavir or
tenofovir. Ritonavir in the presence of another protease inhibitor
was not included in this definition.
The other outcome of interest was time from ART eligibility to
viral load (VL) suppression (within one year). Suppression was
based on a laboratory result report of an HIV-1 RNA level #500
copies/mL. This threshold was used to account for differences in
detection limits of commercial assays over the study period [28].
Variables of interest
For each individual in our study, the two state ADAP features in
place on the date of ART eligibility were assessed and stratified
into dichotomous categories that could be classified as more cost-
containing versus less cost-containing: (1) amount of state funding
provided to the annual ADAP budget (none vs. any); and (2) use of
waiting lists in the state (yes vs. no). Information on state ADAP
features was derived from the results of surveys conducted by the
National Alliance of State and Territorial AIDS Directors
(NASTAD) and published in annual reports [15]. We initially
considered two additional state ADAP features, financial eligibility
criteria for ADAP enrollment and inclusiveness of the state ADAP
drug formulary with respect to commercially available antiretro-
viral drugs, but found limited variation in these variables across
states (Table 1) (e.g., most states have a comprehensive ART
formulary), restricting our ability to assess their impact on the
outcomes of interest. State-level ADAP variables were linked to
individuals by their state of residence at the time of ART eligibility
(i.e., these values varied by time). For three multi-site cohorts, the
state of residence was not available, and the state of the clinic site
was used instead as a proxy. We hypothesized that living in a state
with a less generous ADAP feature would be associated with
delayed ART initiation and virologic suppression (i.e., a hazard
ratio less than one).
Other variables
Other individual-level variables assessed at the time of ART
eligibility and included as potential confounders were age, race/
ethnicity (black; Hispanic; white or other), sex and transmission
risk (men who have sex with men; male IDU; female IDU; male
heterosexual or other risk, female heterosexual or other risk),
CD4+ count, HIV viral load, calendar year, and documented
histories of drug abuse, alcohol abuse, and mental illness. Drug
abuse, alcohol abuse, and mental illness were categorized on the
basis of more specific diagnoses derived from electronic medical
record diagnoses and chart reviews. As potential psychosocial
barriers to ART initiation, they were grouped as a single ordinal
variable, representing the number of barriers experienced [29].
To account for differences in ART initiation influenced by
characteristics of the cohorts or clinics themselves, we categorized
cohorts into the following categories: multi-site clinical cohort,
single-site clinical cohort, and interval cohort. Interval cohorts
differ from clinical cohorts in both timing and data collection;
individuals are followed at specified intervals (e.g., every six
months) that are unrelated to health care visits, and data are
collected according to defined protocols [30]. We also included
two variables representing specific mechanisms undertaken by
individual clinics to assist with access to ART drugs. This
information came from the results of a standardized questionnaire
given in September 2011 to all clinical cohorts contributing data to
this study. Mechanisms were divided into those performed by
Table 1. Comparison of demographic characteristics and AIDS Drug Assistance Program features of U.S. states represented in
study, 2001 and 2009 data.
Characteristic 2001 2009
All U.S. states* 34 states* in study All U.S. states* 34 states* in study
Median IQR Median IQR Median IQR Median IQR
Demographic variables
Population density (per square mile) 90 42–221 137 63–274 100 43–230 150 66–282
% of population that is of black race 7.2 2.3–15.8 10.9 4.1–19.8 7.6 3.1–16.3 11.5 5.3–19.7
Annual household income (current U.S. dollars, thousands) 51,004 46,473–58,205 51,663 47,095–56,861 49,909 45,455–56,568 49,271 45,036–56,853
% of population living below FPL 10.5 8.5–14.1 11.1 8.5–14.2 13.3 10.9–15.8 13.9 11.7–16.6
State Medicaid HIV spending per capita N/A N/A N/A N/A 18,757 15,768–22,710 19,621 16,417–23,088
AIDS Drug Assistance Program (ADAP) features
% state contribution to total ADAP budget expenditures 9 0–21 14 3–28 11 0–25 19 5–31
States contributing to total ADAP budget, by percentage (N, %)
0% N = 15 29% N = 6 18% N = 17 33% N = 8 24%
Less than 20% N = 22 43% N = 17 50% N = 15 29 N = 9 26%
20% or more N = 14 27% N = 11 32% N = 19 37% N = 17 50%
% of all available antiretroviral drugs on formulary 100 100–100 100 100–100 100 97–100 100 97–100
Financial eligibility threshold as % of FPL 300 230–350 300 281–370 300 300–400 300 300–400
States with waiting list at least once during study (N, %) - - - - N = 20 39% N = 11 32%
*Including the District of Columbia.
FPL = federal poverty level, IQR = interquartile range, N/A = not available. State demographic variables from annual U.S. Census population estimates and the Current
Population Survey [31,33]. State Medicaid spending from the Kaiser Commission on Medicaid and the Uninsured and the Urban Institute [32]. ADAP features from the
National Alliance of State and Territorial AIDS Directors (NASTAD) [15].
doi:10.1371/journal.pone.0078952.t001
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clinic staff and those done after referral to entities outside the
clinic. Additional information about the questionnaire is in File S1.
State-specific characteristics related to population demographics
and Medicaid spending may also affect decisions on how ADAPs
are run, as well as ART initiation. To account for these potential
confounding differences, we included the following state variables,
linked to individuals by the year of ART eligibility and categorized
into quartiles: population density [31], the percentage of the
population who are of black race, the percentage of the population
living below the federal poverty line, median household income,
and per capita Medicaid spending on enrollees with HIV.
Medicaid data came from the Henry J. Kaiser Family Foundation
and were available for the years 2007–2009 only [32]. All other
data were available from all years (i.e., these values varied by time)
and came from annual U.S. Census population estimates [31] and
the Current Population Survey [33].
Statistical methods
To estimate the effect of each ADAP characteristic on treatment
outcomes, we used propensity score matching to account for
potential differences between persons living in a state with a
specific ADAP characteristic (‘‘exposed’’ participants) and persons
living in a state without that characteristic (‘‘unexposed’’
participants). Details of the use of this method are included in
File S1. Briefly, for each characteristic, we developed a multivar-
iable logistic regression model to estimate the predicted probability
of living in a state with that feature, controlling for individual- and
clinic-level variables that might confound the relationship between
the exposure and the outcomes of interest. We then matched
exposed participants to comparable unexposed participants based
on the propensity of exposure, using 1:3 nearest neighbor
matching (i.e., matching to the unexposed participant with the
most similar propensity score), with replacement. Balance on
potential confounders between exposed and unexposed partici-
pants was evaluated quantitatively and graphically. Propensity
score matching was performed using the MatchIt package [34] in
R 2.15.0 (R Foundation for Statistical Computing, Vienna,
Austria). After matching, we used Cox regression to examine
differences in the time to ART initiation and time to VL
suppression by each ADAP feature. Models were adjusted for the
propensity score and any additional variables with residual
imbalance, and weighted to account for matching with replace-
ment. The resulting inferences are generalizable to persons who
are similar to those living in states with the less generous ADAP
characteristic, maximizing internal validity in this subset of
individuals [35].
We also performed analyses that did not use propensity score
matching but rather conventional multivariable Cox regression
analysis. Such models may be less able to adjust for known
confounders if there is limited covariate overlap, but use the entire
study population instead of a more limited subset. We also used
conventional Cox regression analysis for our pre-specified
subgroup analysis among IDU, because we could not get adequate
balance on confounders in the propensity score model.
To further explore the relationship between a state contribution
to the annual ADAP budget and increases in ART initiation, we
looked for evidence of a ‘‘dose-response’’ trend in state funding.
Because our propensity score models used logistic regression and
thus require a dichotomous ‘‘treatment’’, we used conventional
Cox models to explore this relationship. We created three levels of
state funding: 0% of the total ADAP budget (i.e., no state
contribution), .0% but ,20%, and 20% or more.
Finally, we performed several sensitivity analyses to examine
assumptions about the relationship between state ADAP charac-
teristics and the outcomes of interest. These included use of
alternate statistical methods, modifications to the exposure
definition, and additional subgroup analyses (see File S1 for
details).
Results
There were 8,874 individuals initially eligible between 2001 and
2009 for inclusion in this analysis. Figure 1 shows the study
selection process used to identify individuals living in states with
the ADAP characteristics under question, and similar individuals
not living in these states, used in propensity score analyses.
Overall, the median age was 40 years, and 74% were men
(Table 2). Among men, 59% reported sex with men as a
transmission risk factor, 14% reported IDU and 27% reported
heterosexual transmission or other risk. Among women, 17%
reported IDU and 83% reported heterosexual or other risk.
Among all individuals, 44% were black, 33% were white, 18%
were Hispanic, and 4% were Asian or of other race/ethnicity. The
overall study population lived in 33 states and the District of
Columbia (Figure 2).
In Table 1, we show state-level demographic and socioeconomic
characteristics based on 2001 and 2009 data of the 34 jurisdictions
represented by the overall study population, as well as a
comparison to the U.S. overall. States in this study were more
densely populated, more diverse with respect to black race, had a
greater percentage of their population living below the federal
poverty line, and spent more Medicaid dollars on HIV per capita.
Table 1 also shows the distribution of selected ADAP features in
these states. The percent state contribution to the state’s total
ADAP budget was not significantly associated with having an
ADAP waiting list.
Regarding the mechanisms undertaken by individual clinics to
assist with access to ART drugs (Table S1 in File S1), clinics on
average had four procedures in place to directly assist their
patients with accessing prescription drugs, including assisting
patients with ADAP enrollment (91%), Medicare Part D, and
Medicaid (both 86%), and pharmaceutical assistance programs
(77%). 64% also had mechanisms in place to refer patients to other
organizations for additional help.
Association between no state ADAP contribution and
treatment outcomes
In the overall study population (N = 8,874), 56% of individuals
initiated ART within six months of eligibility. Persons living in
states not contributing to the ADAP budget were less likely to
initiate ART within six months than persons living in states that
did (39% vs. 58%). Table 3 shows crude and adjusted
conventional Cox regression-based hazard ratios for the associa-
tion between living in a state contributing to its ADAP budget and
ART initiation (adjusted hazard ratio [HR] 0.80 [95% CI 0.69–
0.93]). After propensity score matching, the association between
living in a state with no additional state contribution to the ADAP
budget and delayed ART initiation retained statistical significance
(N = 1,082, HR 0.73, 95% CI 0.60–0.88). We also found a
significant dose-response relationship: compared with living in a
state with a 20% or greater state contribution, the HR for ART
initiation when living in a state with more than 0% but less than
,20% contribution was 0.90 (95% CI 0.82–0.99), and the HR for
no contribution was 0.75 (95% CI 0.63–0.88) (ptrend,0.001). In
the analysis limited to IDU, the adjusted hazard ratio for ART
initiation was 0.67 (95% CI 0.47–0.95), and the dose-response
effect persisted. Other sensitivity analyses examining alternative
approaches or within different subgroups showed generally
State ADAP Features and Treatment Initiation
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consistent findings with the base case results, although some of
these associations did not reach statistical significance (Table S2 of
File S1).
Virologic suppression one year after ART eligibility among the
entire study population was 58%, with those living in states not
contributing to the ADAP budget less likely to have a suppressed
viral load (51% versus 59%). In adjusted analyses, this association
was not statistically significant (conventional Cox regression-
adjusted HR 1.02, 95% CI 0.88–1.18; propensity score-matched
HR 1.13, 95% CI 0.93–1.36).
Association between ADAP waiting lists and treatment
outcomes
Among the overall study population (N = 8,874), ART initiation
after six months was higher among those living in a state with an
existing ADAP waiting list than those living in a state without a list
(73% versus 55%). A similar pattern was observed in this overall
population for one-year virologic suppression (71% versus 58%).
In regression-adjusted analyses, the hazard ratio based on living in
a waiting list state was 1.73 (95% CI 1.45–2.07) for ART initiation
and 1.21 (95% CI 1.01–1.44) for virologic suppression (Table 4).
After propensity score matching to improve exchangeability
between groups, living in a waiting list state was no longer
associated with delayed ART initiation (N = 620, HR 1.12, 95%
CI 0.87–1.45) or virologic suppression (HR 1.05, 0.79–1.38).
However, our analysis among IDU maintained the significant
association between living in a waiting list state and ART initiation
(HR 2.15, 95% CI 1.31–3.55).
We performed a sensitivity analysis to examine whether the
non-significant association was maintained when shortening the
time to ART initiation to 3 months after eligibility instead of 6
months. Here, the HR was 1.44 (95% CI 1.06–1.97) (Table S2 of
File S1). When we did not account for clinic-specific mechanisms
to obtain treatment for patients in the propensity score model, the
associations between living in a waiting list state and our outcomes
of interest were greater and reached statistical significance (HR
1.93, 95% CI 1.49–2.51 for ART initiation, HR 1.29, 95% CI
1.02–1.63 for virologic suppression) compared with the base case
scenario. Thus, additional follow-up time and confounder control
seemed to attenuate the association between living in a waiting list
state and ART initiation.
Discussion
In this study of HIV-infected individuals in the United States
who were newly clinically eligible to begin ART, we found that not
having an additional state contribution to an ADAP’s annual
budget was associated with delayed ART initiation. This finding
was robust to the type of statistical procedure used to account for
known confounders, and furthermore was maintained when
considering different assumptions, and when focusing on specific
subpopulations, including those with a history of IDU.
Our findings are consistent with an ecologic analysis that
suggested greater HIV inequities in some U.S. states as a result of
lower state ADAP contributions [36]. Combining this information
with our a priori hypothesis and the dose-response effect identified,
Figure 1. Flow charts showing selection into each of the two analyses. Gray indicates the population of interest for the propensity score-
matched analyses.
doi:10.1371/journal.pone.0078952.g001
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we believe that we have described a plausible mechanism in
delayed ART uptake. Several reports have noted the importance
of state contributions to ADAP budgets [37,38]. While discretion-
ary federal funds to ADAP are proportionally allocated to states on
the basis of HIV prevalence, in principle to guarantee distribu-
tional equity [39], this metric may not measure all aspects of need
in individual states. The additional funding stream based on state
general revenue may play a role in maintaining the core functions
of the program or help to improve treatment uptake in the target
population, such as the inadequately insured or the working poor.
It could also result in more or better trained ADAP office staff to
work with and follow up with clients or in better ancillary client
services like adherence support.
We found that living in a state with an active ADAP waiting list
was not associated with less timely ART initiation, and in fact, in
some scenarios associated with more timely ART initiation. On
the surface, this may seem paradoxical; we expected that living in
a state with an ADAP waiting list would be associated with less
timely ART initiation. However, this finding may reflect efforts at
study sites contributing data to NA-ACCORD to get patients
promptly treated when there is knowledge of existing structural
barriers. For example, the more timely initiation related to waiting
lists that we observed among IDU could reflect special efforts by
sites to engage this high-need group into care, since it is known
that IDU have lower levels of engagement in HIV care compared
with other risk groups [25]. While we controlled for some clinic-
level behaviors regarding assistance with procurement of ART, we
may not have fully captured the scope of these efforts, since
assessments were conducted retrospectively based on a survey of
participating clinics. Furthermore, additional efforts occurring at
state ADAP offices (e.g., efforts to help people sign up for
pharmaceutical company prescription assistance programs when
being placed on a waiting list, use of other cost-containment
strategies when resources are low) were not assessed in our study.
In our analysis, excluding clinic-based efforts from the propensity
score model resulted in more pronounced and statistically
significant associations between living in a waiting list state and
ART initiation and virologic suppression, suggesting that we at
Table 2. Characteristics of newly treatment-eligible HIV-infected U.S. residents in NA-ACCORD, 2001–2009.
Overall (N = 8,874)
Included in analysis of state
contribution to ADAP budget
(N = 1,082)*
Included in analysis of state
ADAP waiting lists (N = 620)*
N % N % N %
Age at eligibility, years (median, IQR) 40 33–46 41 34–47 37 31–44
18–29 1,555 18 139 13 131 21
30–39 2,869 32 343 32 236 38
40–49 2,989 34 397 37 196 32
50–59 1,216 14 181 17 47 8
60+ 245 3 22 2 10 1.6
Race/ethnicity
Black (non-Hispanic) 3,937 44 617 57 272 44
Hispanic 1,631 18 57 5 40 7
White (non-Hispanic) 2,944 33 382 35 293 47
Other (non-Hispanic) 362 4 26 2.4 15 2.4
Sex and transmission risk
Men who have sex with men 3,839 43 368 34 282 46
Male injection drug user 946 11 210 19 46 7
Male, heterosexual or other risk 1,764 20 162 15 145 23
Female injection drug user 387 4 115 11 12 1.9
Female, heterosexual or other risk 1,938 22 227 21 135 22
Eligibility criteria
CD4+ count 0–199 cell/uL 3,118 35 274 25 224 36
CD4+ count 200–349 cells/uL 5,464 62 775 72 380 61
Incident AIDS-defining illness (i.e., CD4+ count not ,350 cells/
uL)
292 3 33 3 16 2.6
Viral load at eligibility
501–999 copies/mL 152 1.7 12 1.1 6 1
1,000–9,999 copies/mL 1,299 15 156 14 56 9
10,000–99,999 copies/mL 3,743 42 464 43 248 40
100,000+ copies/mL 2,588 29 261 24 162 26
Missing 1,092 12 189 18 148 24
ART = antiretroviral therapy, IQR = interquartile range. Percentages may not add up to 100 due to rounding.
*See Figure 1 for details of study selection procedure.
doi:10.1371/journal.pone.0078952.t002
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least partially accounted for clinic-level factors related to ART
initiation. Having additional information on the mechanisms that
people use to access treatment would further inform this important
data consideration.
We used propensity score matching methods to create
comparable groups of ‘‘exposed’’ and ‘‘unexposed’’ individuals,
capitalizing on the heterogeneity of policies across different states
in the NA-ACCORD. This technique measures the ‘‘average
treatment effect in the treated’’ population, which is different from
the ‘‘average treatment effect’’ in the entire study population that
conventional regression analyses assess. We can interpret our
propensity-score matched estimates regarding state ADAP features
as applicable to the subset of individuals with the same risk factor
distribution as those living in those states with those features (i.e.,
no state contribution to the ADAP budget; presence of ADAP
waiting lists) [40]. Thus, these findings may not necessarily apply
to those with different risk factor distributions, or those who were
not selected as a match. Nonetheless, when we ran conventional
regression models that estimated effects among the entire study
population, the results were generally similar to the propensity
score-based results, lending further support to our conclusions.
We did not find significant associations between less generous
ADAP features and less timely virologic suppression. One
possibility for this is that the majority of HIV-infected individuals
in our population were eventually treated (the percentage
increasing to 65% overall after one year of eligibility), and once
they began treatment, differences in the state ADAP features we
examined may have played less of a role. In other words, the
majority of people reached guideline-defined treatment goals,
despite the delay in starting therapy that more limited state
budgets may influence. This is encouraging, even though the
additional efforts expended to procure treatment in light of these
delays have costs.
Furthermore, we did not report on longer-term outcomes like
sustained viral load suppression and mortality. Because our study
is essentially an intent-to-treat analysis, we did not take into
account changes in ADAP features over the course of an
individuals’ treatment trajectory. An analysis of time-updated
ADAP changes could help to understand these processes better,
especially considering the variability in coverage by some state
ADAPs of medications for other health conditions relevant to
HIV-infected individuals like hepatitis infection, cardiovascular
disease, and mental health conditions [15,41–43].
We originally hypothesized that our effect estimates would be
greater among IDU owing to their increased needs with respect to
care engagement and treatment initiation. While our data provide
some evidence of this, the overall effects are not dramatically
different from those overall, suggesting that on the whole, state-
level differences in the ADAP features we examined may affect
their target populations similarly with respect to ART initiation.
Number of study participants, 








Figure 2. Map of U.S. states represented in study.
doi:10.1371/journal.pone.0078952.g002
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Table 3. Association between living in a state not contributing to the annual ADAP budget and ART initiation and virologic
suppression, U.S. NA-ACCORD, 2001–2009.
Outcome: 6-month ART initiation Outcome: 1-year virologic suppression
HR 95% CI HR 95% CI
Overall
No contribution (vs. any contribution)
Crude (N = 8,874) 0.56 0.49–0.63 0.75 0.67–0.83
Regression-adjusted (N = 8,874) 0.80 0.69–0.93 1.02 0.88–1.18
Propensity score-matched (N = 1,082)* 0.73 0.60–0.88 1.13 0.93–1.36
Dose-response effect (Ptrend) (N = 8,874) ,0.001 0.25
No contribution 0.75 0.63–0.88 1.06 0.91–1.24
Contribution ,20% 0.90 0.82–0.99 1.07 0.97–1.17
Contribution .20% 1.00 Ref. 1.00 Ref.
Injection drug users only (N = 1,824)
No contribution (vs. any contribution)
Crude 0.40 0.31–0.51 0.78 0.64–0.96
Regression-adjusted 0.67 0.47–0.95 1.14 0.82–1.59
Dose-response effect (Ptrend) 0.005 0.29
No contribution 0.58 0.40–0.86 1.21 0.83–1.74
Contribution ,20% 0.81 0.63–1.04 1.10 0.85–1.42
Contribution .20% 1.00 Ref. 1.00 Ref.
ART = antiretroviral therapy, CI = confidence interval, HR = hazard ratio.
All analyses use Cox proportional hazards regression.
*Hazard ratios obtained after 1:3 matching (with replacement) 683 ‘‘exposed’’ to 399 ‘‘unexposed’’ individuals based on propensity of living in a state contributing to
the ADAP budget.
Both regression-adjusted and propensity-score matched analyses account for the following variables: age; sex; race/ethnicity; transmission risk; CD4+ count and viral
load at eligibility; history of alcohol abuse, substance abuse, and mental disorders; year of eligibility; type of cohort; clinic-specific mechanisms to help obtain ART; state-
level population density, % population of black race, % population below poverty line, median household income, and per capita Medicaid spending on HIV.
doi:10.1371/journal.pone.0078952.t003






HR 95% CI HR 95% CI
Overall
Living in a waiting list state (vs. not living in a waiting list state)
Crude (N = 8,874) 1.55 1.38–1.73 1.39 1.24–1.57
Regression-adjusted (N = 8,874) 1.73 1.45–2.07 1.21 1.01–1.44
Propensity score-matched (N = 620)* 1.12 0.87–1.45 1.05 0.79–1.38
Injection drug users only (N = 1,824)
Living in a waiting list state (vs. not living in a waiting list state)
Crude 1.59 1.19–2.11 1.49 1.10–2.03
Regression-adjusted 2.15 1.31–3.55 1.30 0.80–2.09
ART = antiretroviral therapy, CI = confidence interval, HR = hazard ratio.
All analyses use Cox proportional hazards regression.
*Hazard ratios obtained after 1:3 matching (with replacement) 398 ‘‘exposed’’ to 222 ‘‘unexposed’’ individuals based on propensity of living in a waiting list state.
Both regression-adjusted and propensity-score matched analyses account for the following variables: age; sex; race/ethnicity; transmission risk; CD4+ count and viral
load at eligibility; history of alcohol abuse, substance abuse, and mental disorders; year of eligibility; type of cohort; clinic-specific mechanisms to help obtain ART; state-
level population density, % population of black race, % population below poverty line, median household income, and per capita Medicaid spending on HIV.
doi:10.1371/journal.pone.0078952.t004
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However, it is possible that other differences in state ADAP
formularies, such as coverage of hepatitis treatment or opioid
dependency [23,44], could influence outcomes more likely to
affect IDU such as liver disease and drug overdose, and this is
worth exploring.
Recent observational studies have taken other approaches to
understand the influence of ADAP features, directly examining
the benefits of ADAP enrollment itself on treatment utilization
[42,45,46]. For example, the Women’s Interagency HIV Study
found increased use of ART among HIV-infected women
enrolled in an ADAP versus those not enrolled, even after
adjusting for insurance status [42]. A study from the 1917 Clinic
in Alabama found that many ADAP enrollees, despite having
ART available to them, still use ART suboptimally [45].
Because these studies focused on ADAP enrollment as an
exposure itself, they examined pathways related to successful use
of treatment as a consequence of enrollment. Our analysis
complements these studies by providing information on earlier
mechanisms that are a function of the state-related features of
the ADAPs themselves, to address potential barriers to ADAP
enrollment and therefore timely initiation of treatment. Our
study is the largest to date examining the role of ADAP on
treatment outcomes. Importantly, six of the ten states with the
highest ADAP enrollments in the country were among the
largest ten states represented in our study population (Califor-
nia, New York, Florida, Texas, Illinois, Pennsylvania) [18]. We
also used consistent methods across states in our analysis, which
would be more difficult to accomplish systematically using data
from individual state programs [47]. However, our study has
limitations. First, although NA-ACCORD sites are diverse and
represent a variety of research settings [26,48], many of the
participating clinics are located at major academic centers, and
therefore our inferences may be less generalizable to patients
not seen at such clinics. However, we are reassured somewhat
by the fact that many of these sites are responsible for the
majority of HIV care in their respective catchment areas, and
therefore are applicable to a large proportion of the general
HIV-infected population. Second, because information on
individual-level socioeconomic status or insurance status (in-
cluding actual ADAP enrollment itself for each of the
participants) was not available, our study population includes
both people who are financially eligible for ADAP services (i.e.,
lower income) and people who may not qualify for assistance
(i.e., higher income). Thus, we could not specifically study the
subset of our population that was the true population at risk.
Because of the ecologic nature of this analysis, the effects we
estimated could be considered ‘‘contextual’’ effects, in that they
apply to those living in the state during which a particular
ADAP feature was in place, and not just those who were actually
enrolled in an ADAP. Nonetheless, such contextual effects are
useful since they suggest benefits from policies that go beyond
the narrower population of ADAP enrollees.
Another limitation is that our exposures of interest were based
on the results of annual surveys of state ADAP offices conducted
by NASTAD over the study period and therefore are dependent
on the quality of these findings. However, these results are publicly
available and therefore allow for transparency should similar
assessments be conducted by other investigators. Unmeasured
confounding may have also affected our effect estimates. Both
propensity score matching and conventional regression techniques
are designed to account for observed confounders, but there may
be other characteristics of patients, clinics, or the states themselves
that we have not accounted for in our analysis. For example, we
did not account for the diffusion of each state’s ADAP program
among its HIV-infected population, or more nuanced differences
in state Medicaid eligibility or generosity beyond per capita HIV
spending, which if important could lead to some bias in our
conclusions. In sensitivity analyses, we controlled for state fixed
effects to try to account for all of the unobserved characteristics of
a particular state, but by doing so this technique may have over-
adjusted for these effects, which may have been highly correlated
with the exposure of interest.
Finally, the period of eligibility for this analysis ended in 2009,
when at least two major changes occurred in the HIV epidemic in
the United States: the adoption of clinical guidelines recommend-
ing starting treatment at a CD4+ count of 500 cells/uL or even
higher [49], and a substantial rise in the number of people in the
U.S. on ADAP waiting lists in 2010 and 2011, due to state-level
economic crises [15,18]. While better understanding of more
recent changes is needed, our analysis nonetheless covered a
significant portion of the history of the ADAP program. Future
work should monitor ongoing changes to the healthcare funding
landscape [50].
In conclusion, our study found an association between living in
a state that does not provide an additional contribution to ADAP
funding and delays in ART initiation. The importance of timely
ART initiation when clinically indicated is well-established [17].
Many factors complicate the healthcare environment for people
with HIV infection in the United States, including competition for
resources as more people are tested and treated earlier [51,52] and
evolving trends in health insurance coverage [53], which will likely
further change as Medicaid eligibility expands with the imple-
mentation of the Patient Protection and Affordable Care Act [54–
56]. Because of these changes, more research on the impact of
budgetary differences on the effectiveness of state ADAPs in
providing timely therapies is clearly warranted, particularly for the
groups that need this assistance the most. Such additional
information may help ADAPs to better manage their resources
and best serve the needs of their target populations.
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